

## **Dr. Miguel Castilla Marti, MD**

Deputy medical director of Vista Alpina eye center

### **Training and professional background**

- 04/2022 - Deputy medical director, Vista Alpina eye center, Visp, Switzerland
- 5/2018 - 04/2022 worked as an Assistant Physician and Surgeon in the Retina section of Hospital de l'Esperanca, Parc de Salut Mar, Barcelona
- 2016 Doctor of Medicine - PhD  
Title: Impact of vitreous floaters on visual quality  
Excellent Cum Laude. UAB Barcelona
- 03/2015 - Consultant ophthalmologist and head of research at NORFACE project (Neuro-Ophthalmology Research at Fundacio ACE), ACE Foundation - Barcelona Alzheimer's Treatment and Research Center, Barcelona
- 06/2014 - 04/2022 working as a physician ophthalmologist specializing in retina and investigator at Valles Ophthalmology Research (VOR), Hospital General de Catalunya
- 06/2014 - 05/2018 worked as an Assistant Physician in the Retina section of the Comprehensive Service of Ophthalmology of Eastern Valles (SIOVO)
- 2012 - 2014 Fellowship in medical, surgical retina and intraocular inflammation at MIOS - Centre specialise en retine et inflammation oculaire (Prof MD de Smet). Lausanne, Suisse
- 05/2013 European Accreditation FEBO (Fellow of the European Board of Ophthalmology)
- 2008 - 2012 Medical resident in ophthalmology H.G.U Gregorio Maranon, Madrid, Spain
- 2011 Research sufficiency  
Title: Titol: Luxació del complexe lent intraocular-sac capsular: sèrie de casos. UAB, Barcelona
- 2001 - 2007 Degree in Medicine and Surgery - UAB, Barcelona  
Very good 11, Excellent 5, Honors 2

### **Membership to scientific societies**

Member of Spanish National Societies: SEO, SERV, SECOIR  
Member of international Societies: EURETINA, ESCRS, ARVO

## Awards

- 2017 Award for the best video at the EURETINA meeting video competition awards September 2017, Barcelona
- 2013 Award for best panel presentation at the European Society Congress of Ophthalmology SOE2013, section: Education, Electrophysiology and Neuro-ophthalmology June 2013, Copenhagen
- 2012 Award for the best classic video of the XIIth National Video Ophthalmology Festival May 2012, Lleida
- 2011 SECOIR Annual Scholarship for young researchers 2011

## Published papers

- 2022 Herranz-Cabarcos A, Quiroz Quiroga M.J, Castilla-Marti, M. et al. Vitrectomy with subretinal tissue plasminogen activator (r-TPA) and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) for submacular hemorrhages treatment: Retrospective analysis of 22 cases. Archivos de la Sociedad Espanola de Oftalmologia. 2022
- 2022 Herranz-Cabarcos A, Vega-Lopez Z, Castilla-Marti, M. et al. Macular optical coherence tomography for screening of pathology prior to cataract surgery: An approach based on teleevaluation. European Journal of Ophthalmology. February 2022
- 2020 Marquie, M., Valero, S., Castilla-Marti, M. et al. Association between retinal thickness and  $\beta$ -amyloid brain accumulation in individuals with subjective cognitive decline: Fundacio ACE Healthy Brain Initiative. Alz Res Therapy 12, 37 (2020)
- 2020 Sanchez, D., Castilla-Marti, M., Marquie, M. et al. Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Sci Rep 10, 1580 (2020)
- 2018 Marquie, M., Castilla-Marti, M., Valero, S. et al. Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Sci Rep9, 8698.
- 2018 Sanchez, D., Castilla-Marti, M., Rodriguez-Gomez, O. et al. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Sci Rep 8, 16345.
- 2018 Josep Tuni-Picado, Ana Martinez-Palmer, Xenia Fernandez-Sala, Jaime Barcelo-Vidal, Miguel Castilla-Marti, Yasmin Cartagena-Guardado, Santiago Grau. Infectious postoperative endophthalmitis after cataract surgery performed over 7 years. The role of azithromycin versus ciprofloxacin eye drops. Rev Esp Quimioter 2018; 31(6): 499-505

- 2018 Agnieszka Dyrda, Ana Martinez-Palmer, Daniel Martin-Moral, Amanda Rey, Antonio Morilla, Miguel Castilla-Marti, and Janny Arones-Santivanez. "Clinical Results of Diffractive, Refractive, Hybrid Multifocal, and Monofocal Intraocular Lenses," *Journal of Ophthalmology*, vol. 2018, Article ID 8285637, 12 pages, 2018.
- 2018 Marc D. de Smet, Miguel Castilla-Marti, Re: van Bree et al.: Straylight as an Indicator for Cataract Extraction in Patients with Retinal Dystrophy. *Ophthalmology Retina*, Volume 2, Issue 8, 2018, Page e9. ISSN 2468-6530.
- 2018 Sararols L, Banon K, Londono G, Castilla M, Guarro M: Posterior Hyaloid Dissection: Let's Make It Easy with Blue. *Ophthalmologica* 2018; 239:231-232.
- 2015 Pazos M, Poposki V, Castilla-Marti M, Nahra D, Martinez-Palmer A. Astigmatic reduction and corneal power effect of opposite clear corneal incisions at the time of cataract surgery. *MJO* 2015; vol.2 22-29.
- 2015 Martinez-Palmer A, Castilla-Marti M, Martin-Moral D, Calsina-Prat M, Poposki V. Pupil size in lens surgery candidates. *MJO* 2015; vol.2 15-20.
- 2015 Castilla-Marti M, de Smet MD, Rojas Lozano MaPilar. Tratamiento precoz de la oclusion de rama venosa retiniana con edema macular con implante intravitreo de dexametasona (Ozurdex). *Casos clinicos en retinopatias* 5-8.
- 2015 Castilla-Marti M, Van den Berg TJ, de Smet MD. Effect of vitreous opacities on straylight measurements. *Retina* 2015 Jun; 35(6):1240-6.
- 2013 de Smet MD, Castilla-Marti M. Ocriplasmin for diabetic retinopathy. *Expert Opin Biol Ther* 2013; 13(12):1741 7.

### Research and clinical trials

- Study to observe the effectiveness and safety of ranibizumab through individualized patient treatment and associated outcomes. LUMINOUS. Investigator
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual
- impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV). MINERVA. Investigator
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor(VEGF) driven macular edema (ME). PROMETHEUS. Investigator

- A 12-month, phase IIIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration. TREND. Investigator
- Phase IV trial to evaluate the efficacy of aflibercept in patients with age-related macular Degeneration (ARMD) neovascular without optimal response to repeated monthly intravitreal injections anti-VEGF-A. MACBETH. Investigator
- A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of FOVISTA (anti PDGF-B PEGYLATED APTAMER) administered in combination with Lucentis compared to Lucentis Monotherapy in subjects with subfoveal neovascular age-related macular degeneration. OPH1003 (ECLIPSE). Investigator
- Combined study Phases IIa / IIb to evaluate efficacy, security and tolerability of repeated doses of topical drops of regorafenib in patients with naive Exudative Age related Macular Macular Degeneration. BAYER 73-4506, DREAM STUDY. Investigator
- Study M-13-056 Evaluacion de los resultados anatomicos y funcionales en pacientes tratados con ocriplasma para la traccion vitreomacular/adhesion vitreomacular sintomatica (TVM/AVMs). Investigator
- OPH1004 - A phase 3 randomized, double masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular AMD. Investigator
- RTH258-C002 - A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study
- Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. Investigator
- AQUA - An open-label Phase 4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment. Investigator
- VIOLET - An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME). Investigator
- COLUMBUS: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (DMAE). Investigator
- CENTERA: A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion. Investigator

- LAMPALIZUMAB: Estudio de fase II multicentrico, randomizado, con doble enmascaramiento, controlado con simulacion, para evaluar la eficacia y seguridad de LAMPALIZUMAB administrado en inyeccion intravitrea a pacientes con atrofia geografica secundaria a degeneracion macular relacionada con la edad. Investigator
- CIRCLE: A Phase 2, randomised, double-masked, sham-controlled, multi-center study to evaluate the efficacy and safety of ocriplasmin in inducing total posterior vitreous detachment (PVD) in subjects with non-proliferative diabetic retinopathy (NPDR). Investigator
- Safety and efficacy of Abicipar Pegol (AGN-150998) in Patients with neovascular Age-related macular degeneration. Investigator
- A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion. SAPHIRE. Investigator
- Other ongoing studies where I'm working as investigator are: Diabetic Macular Edema (RHINE), Diabetic Macular Edema (KESTREL), Neovascular Age-related Macular Degeneration (XPLORE), Neovascular Age-related Macular Degeneration (TALON), Branch Retinal Vein Occlusion (RAPTOR), Geographic Atrophy Secondary to AMD (GTSCOPE)